Key result
Immunohistochemistry demonstrated that lesional cells in 80% (12 of 15) of sporadic superficial angiomyxoma cases were non-reactive to antibodies against PRKAR1A.
Why the study?
Superficial angiomyxomas can be associated with Carney complex and PRKAR1A mutations, prompting the authors to characterize PRKAR1A expression in sporadic cases.
Observational (n=15)
Sporadic superficial angiomyxomas frequently demonstrate loss of PRKAR1A expression, suggesting a role for this gene in non-syndromic tumor development.
Superficial angiomyxomas merit CNC screening in atypical presentations; leaves open the prevalence and genetic drivers of sporadic cases.
Superficial angiomyxomas are cutaneous mesenchymal tumours that typically present clinically as slow-growing, solitary, asymptomatic nodules that can occur at any age. Histopathologically, these dermal and subcutaneous tumours are characterized by abundant myxoid stroma, numerous thin-walled and often arbourising blood vessels, and spindled to stellate fibroblast-like cells. While usually sporadic, superficial angiomyxomas can occasionally be associated with Carney complex (CNC), an autosomal dominant disorder characterized by inactivating germline mutations in the 1-alpha regulatory subunit of protein kinase A (PRKAR1A) and various clinical manifestations, including cardiac myxomas, facial lentigines, epithelioid blue naevi, endocrinopathies and psammomatous melanotic schwannomas. In this study, we sought to characterize the presence or absence of PRKAR1A expression by immunohistochemistry (IHC) in sporadic superficial angiomyxomas based on our observations in an index case. In total, PRKAR1A immunohistochemical expression was determined in 15 sporadic superficial angiomyxoma cases retrieved from the surgical pathology archives. IHC demonstrated that the lesional cells in 12 cases (80%) were non-reactive to antibodies against PRKAR1A. This study provides evidence in support of a role for PRKAR1A in the development of clinically non-syndromic superficial angiomyxomas. Together with previous studies, this report demonstrates that PRKAR1A may play an important role in the development of a variety of myxomatous mesenchymal tumours.
No takes yet. Share an insight, caveat, or question.
Hafeez et al. (2021) conducted an observational in Sporadic superficial angiomyxomas (n=15). PRKAR1A expression by immunohistochemistry was evaluated on PRKAR1A immunohistochemical expression. Immunohistochemistry demonstrated that lesional cells in 80% (12 of 15) of sporadic superficial angiomyxoma cases were non-reactive to antibodies against PRKAR1A.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: